Phone: +49 (0)345 27996330
Fax: +49 (0)345 27996332
Scil Proteins focuses on the development of biotherapeutics applying its proprietary Affilin® technology for its own pipeline as well as in collaboration with pharmaceutical partners. Affilin® molecules are based on the human Ubiquitin scaffold and engineered to generate de-novo binding affinity towards disease-relevant targets. The platform allows the generation of agonistic or antagonistic binding molecules, their fusion to effector molecules or multispecific designs. Thus, Affilin® molecules present an attractive alternative or complement to conventional antibody formats, broadening the application space of biotherapeutics.